9MII image
Entry Detail
PDB ID:
9MII
EMDB ID:
Keywords:
Title:
253-7A03 Fab in complex with HIV-1 BG505 SOSIP Env trimer and RM20A3 Fab
Biological Source:
PDB Version:
Deposition Date:
2024-12-12
Release Date:
2025-05-21
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:HIV-1 Envelope Glycoprotein BG505 SOSIP.664 gp120
Chain IDs:A, E (auth: C), I (auth: E)
Chain Length:516
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:Envelope glycoprotein gp160
Chain IDs:B, F (auth: D), J (auth: F)
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:RM20A3 heavy chain Fv
Chain IDs:C (auth: G), G (auth: J), K (auth: M)
Chain Length:125
Number of Molecules:3
Biological Source:Macaca mulatta
Polymer Type:polypeptide(L)
Description:253-7A03 heavy chain Fv
Chain IDs:M (auth: H)
Chain Length:119
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:RM20A3 light chain Fv
Chain IDs:D (auth: I), H (auth: K), L (auth: N)
Chain Length:128
Number of Molecules:3
Biological Source:Macaca mulatta
Polymer Type:polypeptide(L)
Description:253-7A03 lambda chain Fv
Chain IDs:N (auth: L)
Chain Length:100
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01B, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, that target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures